Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2626 to 2640 of 9098 results

  1. Cagrilintide–semaglutide for managing overweight and obesity

    Awaiting development Reference number: GID-TA12443 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Ivonescimab for untreated metastatic non-small-cell lung cancer with high PD-L1 expression

    Awaiting development Reference number: GID-TA12444 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Corticosteroid-releasing bioabsorbable stent or spacer insertion during endoscopic sinus surgery to treat chronic rhinosinusitis

    In development Reference number: GID-HTG10902 Expected publication date: TBC

    HealthTech guidance
    In development

  4. Hearing aids for adults with hearing loss

    In development Reference number: GID-HTG10886 Expected publication date:  04 February 2027

    HealthTech guidance
    In development

  5. Exploratory economic modelling of SARS-CoV-2 viral detection point of care tests and serology tests

    In development Reference number: GID-HTG10898 Expected publication date: TBC

    HealthTech guidance
    In development

  6. Domestic Abuse

    In development Reference number: GID-NG10449 Expected publication date:  23 February 2027

    NICE guideline
    In development

  7. Dabrafenib with trametinib for treating BRAF V600E mutation-positive advanced differentiated thyroid cancer after radioactive iodine and 1 or 2 VEGFR-targeted treatments

    Awaiting development Reference number: GID-TA12461 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Xanomeline tartrate–trospium chloride for treating schizophrenia ID6716

    In development Reference number: GID-TA11925 Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Neurostimulation of lumbar multifidus for refractory chronic low back pain with lumbar multifidus dysfunction

    In development Reference number: GID-HTG10168 Expected publication date: TBC

    HealthTech guidance
    In development

  10. Topical tapinarof for treating mild to severe plaque psoriasis ID6712: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 30 June 2026.

    Technology appraisal guidance
    In consultation

  11. Resmetirom for treating non-alcoholic steatohepatitis and liver fibrosis [ID6529]: draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 30 June 2026.

    Technology appraisal guidance
    In consultation

  12. Topical tapinarof for treating mild to severe plaque psoriasis ID6712

    In development Reference number: GID-TA11951 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Resmetirom for treating non-alcoholic steatohepatitis and liver fibrosis [ID6529]

    In development Reference number: GID-TA11414 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Digital technologies for the early detection and initial diagnosis of adult hearing loss (provisional title)

    In development Reference number: GID-HTG10172 Expected publication date: TBC

    HealthTech guidance
    In development

  15. Teclistamab for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6628: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 29 June 2026.

    Technology appraisal guidance
    In consultation